Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Feb;66(2):189-94.
doi: 10.1136/ard.2006.057018. Epub 2006 Sep 19.

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment

A S Russell  1 , G V Wallenstein, T Li, M C Martin, R Maclean, B Blaisdell, K Gajria, J C Cole, J-C Becker, P Emery
Affiliations
Randomized Controlled Trial

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment

A S Russell et al. Ann Rheum Dis. 2007 Feb.

Abstract

Objective: To examine the impact of added abatacept treatment on health related quality of life (HRQoL) in patients with rheumatoid arthritis (RA) who have inadequate response to methotrexate (MTX).

Methods: The impact of abatacept treatment on HRQoL was examined in a longitudinal, randomised double blind, placebo controlled clinical trial. Effects of treatment on HRQoL were examined using repeated measures analysis of covariance and comparing rates of change in HRQoL across treatment groups. The relationship between American College of Rheumatology (ACR) clinical markers and disease duration with changes in HRQoL indicators was also examined. Finally, a responder analysis was used to examine the percentage of patients who improved by 0.5 SD in 12 months or who reached the normative levels seen in the US general population.

Results: Statistically significant improvements in the abatacept group relative to controls were observed across a range of HRQoL measures, including physical function, fatigue, all eight domains of the SF-36, and the physical and mental component summaries (PCS and MCS). Improvements were seen as early as day 29 for fatigue and for five out of eight SF-36 domains. By day 169, all HRQoL measures were significantly better with abatacept than with placebo. HRQoL gains were associated with greater ACR clinical improvement, and the effects were consistent for patients with different disease duration. A significantly greater percentage of patients treated with abatacept reached normative levels of PCS, MCS, physical functioning, and fatigue compared with patients treated with MTX alone.

Conclusion: Combined abatacept and MTX treatment produces significant improvements across a wide range of HRQoL domains in patients with RA.

PubMed Disclaimer

References

    1. Spector T D. Rheumatoid arthritis. Rheum Dis Clin North Am 199016513–537. - PubMed
    1. Lee D M, Weinblatt M E. Rheumatoid arthritis. Lancet 2001358903–911. - PubMed
    1. Fuchs H A, Kaye J J, Callahan L F, Nance E, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 198916585–591. - PubMed
    1. Sherrer Y S, Bloch D A, Mitchell D M, Young D Y, Fries J F. The development of disability in rheumatoid arthritis. Arthritis Rheum 198629494–500. - PubMed
    1. Dickens C, McGowan L, Clark‐Carter D, Creed F. Depression in rheumatoid arthritis: a systematic review of the literature with meta‐analysis. Psychosom Med 20026452–60. - PubMed

Publication types

MeSH terms